SRRK Scholar Rock Holding Corp
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1727196 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-17.0%
TTM EPS YoY-2.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-71,732.3%
Net margin-72,563.2%
FCF margin-54,370.7%
EBITDA margin-71,501.6%
Returns
ROE-200.0%
ROA-96.4%
ROIC (approx.)-1,144.3%
Asset turnover0.00x
Leverage & solvency
Liabilities / assets62.2%
Debt / equity1.16x
Current ratio5.41x
Interest coverage-29.23x
Cash quality & payout
Operating cash flow / net income0.75x
Accruals ratio-24.2%
Payout ratio—
Capex / revenue35.4%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $0 | — |
| R&D expense | $208.44M | $184.55M |
| SG&A expense | $176.21M | $67.50M |
| Operating income | -$384.64M | -$252.05M |
| Interest expense | $6.89M | $6.84M |
| Pretax income | -$377.73M | -$246.29M |
| Net income | -$377.94M | -$246.29M |
| EBITDA | -$382.99M | -$250.12M |
| EPS (basic) | -3.29 | -2.47 |
| EPS (diluted) | -3.29 | -2.47 |
| Weighted avg. shares (diluted) | 114.70M | 99.84M |
| Balance sheet | ||
| Cash & equivalents | $323.53M | $180.28M |
| Short-term investments | $44.04M | $259.40M |
| Receivables | $0 | — |
| Inventory | $0 | — |
| Current assets | $385.15M | $451.17M |
| PP&E, net | $1.71M | $2.76M |
| Total assets | $404.27M | $474.92M |
| Current liabilities | $55.42M | $46.94M |
| Long-term debt | $99.71M | $50.15M |
| Total debt | $99.71M | $50.15M |
| Total liabilities | $158.78M | $106.29M |
| Shareholders' equity | $245.49M | $368.63M |
| Net debt | -$223.82M | -$130.14M |
| Shares outstanding | 108.46M | 93.82M |
| Cash flow statement | ||
| Operating cash flow | -$300.04M | -$200.95M |
| Capital expenditure | $602,000 | $98,000 |
| Free cash flow | -$300.64M | -$201.05M |
| Investing cash flow | $218.69M | -$76.06M |
| Financing cash flow | $228.40M | $353.03M |
| Depreciation & amortization | $1.66M | $1.94M |
| Stock-based compensation | $75.60M | $36.63M |
Free plan shows the latest 2 periods; Pro shows all 9 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.